Stay updated with breaking news from Bedema. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Targeting senescent cells in the retina with a BCL-xL inhibitor shows promise as a durable treatment for diabetic macular edema, potentially offering long-term visual function improvements.
Researchers reviewed existing data on rosacea management using botanicals.
Findings from a pioneering study in The American Journal of Pathology, published by Elsevier, reveal that administration of the neuropeptide α-melanocyte-stimulating hormone (α-MSH) promotes corneal healing and restores normal eye function to an otherwise degenerating and diseased cornea by providing protection against cell death and promoting cell regeneration.
Thanks to recent medical breakthroughs, there are now multiple ways to treat macular edema, including medications, laser therapy, and surgery.
To fill gaps in knowledge of yellow fever (YF), a group of researchers in Brazil affiliated with the Department of Pathology at the University of São Paulo's Medical School (FM-USP), Hospital das Clínicas (HC, the hospital complex run by FM-USP), the Heart Institute (InCor, linked to HC) and Emílio Ribas Institute of Infectious Diseases (IIER) decided to study the pathogenesis of YF-associated heart injury.